App/Fresenius K Patent-Cliff Exposure & CMS Drug Spending Portfolio

App/Fresenius K (US): 10 reconciled FDA prescription therapies, $28.0M 2024 CMS Part D & Medicaid spend, and 7 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies10
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$28.0M
2024 Medicare Part D Spend$58K
2024 Medicaid Spend$27.9M
California HCAI SB 17 Filings7 WAC filings (max 31.0% 2-yr change)